Table 2.
Baseline characteristics and treatment of patients included in the efficacy analysis
| Demographic characteristic | n = 94 |
|---|---|
| Gender (n and % of patients) | |
| Male | 37 (39.4%) |
| Female | 57 (60.6%) |
| Age (years) | |
| Mean (SD) | 46.1 (16.1) |
| Race (n and % of patients) | |
| Caucasian | 94 (100.0%) |
| History of GORD symptoms (months) | |
| Mean (SD) | 56.1 (97.9) |
| Duration of current episode of GORD (weeks) | |
| Mean (SD) | 9.53 (8.78) |
| Frequency of heartburn in last week (days) | |
| Mean (SD) | 4.4 (2.3) |
| Previous PPI (n and % of patients) | |
| Lansoprazole 30 mg | 25 (26.6%) |
| Omeprazole 20 mg | 67 (71.3%) |
| Rabeprazole 40 mg | 2 (2.1%) |
GORD, gastro-oesophageal reflux disease; PPI, proton pump inhibitor.